stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Shares outstanding
Erasca, Inc.'s shares outstanding at the end of fiscal 2025 was $283.5M, up 21.3% from $233.8M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $311.3M. Over the past ten years it has ranged from $21.0M (fiscal 2020) to $283.5M (fiscal 2025) — the current reading is the highest in ten years. Erasca, Inc. ranks 21st of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $283.5M | 21.26% |
| FY2024 | $233.8M | 55.69% |
| FY2023 | $150.2M | 23.08% |
| FY2022 | $122.0M | 84.07% |
| FY2021 | $66.3M | 215.10% |
| FY2020 | $21.0M | (82.31%) |
| FY2019 | $119.0M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $311.3M | 2.31% |
| Mar 2026 | $304.3M | 7.33% |
| Dec 2025 | $283.5M | (0.05%) |
| Sep 2025 | $283.7M | 0.11% |
| 21 more quarters | Free account |
Against its own ten years
Low $21.0M
High $283.5M
Ten-year median
$122.0M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ERAS Erasca, Inc. | $311.3M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | $193.8M |
| COGT Cogent Biosciences, Inc. compare | $171.0M |
| EWTX Edgewise Therapeutics, Inc. compare | $120.9M |
| DFTX Definium Therapeutics, Inc. compare | $110.7M |
| CRSP CRISPR Therapeutics AG compare | $96.7M |
| TVTX Travere Therapeutics, Inc. compare | $94.6M |
| DNTH Dianthus Therapeutics, Inc. compare | $57.3M |
| MANE Veradermics Incorporated compare | $40.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item